Outcome of transplanted vs matched nontransplanted patients. (A) Kaplan-Meier estimated DFS for transplanted (red) and nontransplanted (blue) patients. (B) Cumulative incidence of TRM for transplanted patients. (C) Mean cumulative number of REs and (D) cumulative incidence probability for death from all causes in transplanted (red) vs matched nontransplanted control (blue) patients. DFS was defined as time between baseline and IEI-related events (events defined as infection requiring hospitalization, severe autoimmune or inflammatory manifestation, or malignancy) or death, whichever occurred first. For analysis of REs, an event was defined as an IEI-related severe complication (including infection requiring hospitalization, severe autoimmune or inflammatory manifestation, or malignancy) or a transplant-related severe event (including grade 3/4 acute GVHD and extensive chronic GVHD, graft failure, CD34⁺ top-up, donor lymphocyte infusion, secondary malignancy, posttransplant lymphoproliferative disease, and viral reactivations requiring systemic antiviral or cellular therapy).